This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Type 2B (familial) hyperlipidaemia

Authoring team

Type 2B hyperlipidaemia - also known as familial combined hyperlipidaemia - is a mixed hyperlipidaemia: (1)

  • raised plasma cholesterol (raised LDL)
  • raised triglyceride (raised VLDL)
  • there may be isolated increases in apolipoprotein B (apoB)
  • has a multigenic mode and complex inheritance (2)
  • there is an increased risk of ischaemic heart disease

The estimated prevalence is approximately 0.5 to 4%. (3)

Reference

  1. Vaverková H, Karásek D. Familial combined hyperlipidemia - the most common genetic dyslipidemia in population and in patients with premature atherothrombotic cardiovascular disease]. Vnitr Lek. 2018 Winter;64(1):25-29.
  2. Taghizadeh E et al. Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: A review. J Cell Biochem. 2019 Jun;120(6):8891-8898
  3. Trinder M, Vikulova D, Pimstone S, Mancini GBJ, Brunham LR. Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia. Atherosclerosis. 2022 Jan;340:35-43.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.